Nevertheless, the development of targeted therapies for the inhibition of the receptor tyrosine kinases has transformed diagnosis and treatment of adenocarcinoma, whereas similar advances have not yet been achieved in targeting alternative oncogenic pathways in other types of lung cancer. Here, NTRK1 is linked to adenocarcinoma.